Sanofi is in advanced talks to buy Actelion for about $275 a share, or $29.6 billion, people familiar said. Actelion closed at 197.50 Swiss francs ($191.77) yesterday. The price may include a payout for Actelion shareholders contingent on the future performance of certain pipeline drugs. The Swiss drugmaker had earlier received an offer of $250 a share from Johnson & Johnson, which walked away on Tuesday. A deal could be announced as soon as next week.